BTIG has singled out Guardant Health as its leading selection in healthcare, reaffirming a Buy recommendation and modestly increasing its 12-month price objective from $190 to $195. The firm pointed to Guardant’s recent quarterly performance and revised outlook as the basis for the upgrade in conviction.
In its review, BTIG emphasized companies that demonstrate clear leadership within niche areas of healthcare, with particular attention to firms advancing diagnostic innovation and cementing market positions. Guardant stood out to BTIG because of its performance in specialty diagnostics and its traction across oncology testing volumes.
Quarterly performance and guidance
Guardant reported second-quarter revenue of $335 million, a 44% increase year-over-year, and raised its guidance for the full year. The quarter’s results were supported by a 63% rise in core oncology testing volume, a metric BTIG highlighted as a key indicator of demand. That combination of top-line growth and accelerating volume prompted several other firms, including Stifel and TD Cowen, to lift their own price targets.
BTIG’s view of Guardant’s market position
BTIG characterized Guardant as a "must own" company in the specialty diagnostics segment and said it dominates the liquid biopsy market. The firm pointed to Guardant’s broad clinical trial program, including the roughly 20,000-patient prospective ECLIPSE study focused on early colorectal cancer detection, as evidence of the company’s scale in building clinical validation.
Guardant’s commercial portfolio cited by BTIG includes the therapy-selection test Guardant360 CDx as a core offering, alongside other products such as Guardant Reveal, Guardant360 Tissue, the Guardant360 Response monitoring test, and GuardantOMNI for biopharma clients. BTIG expects Guardant to scale these products across additional cancer types and clinical settings and to expand applications internationally.
Near-term catalysts and timelines
BTIG outlined several catalysts that could support further momentum. A potential Centers for Medicare & Medicaid Services (CMS) decision to provide coverage for Reveal MRD for breast cancer as well as for immunotherapy and chemotherapy monitoring would be material. Guardant is also planning a product rollout timeline that BTIG highlighted: the company is on track to introduce Reveal Ultra MRD in the second half of 2026.
Separately, Guardant has received FDA clearance for its G360 Smart Liquid test and is pursuing Advanced Diagnostic Laboratory Test (ADLT) status for that assay at a higher price point, with an anticipated launch in the first half of 2027 should that pathway be achieved.
Outlook
BTIG’s analysis positions Guardant as a leading name in liquid biopsy and precision oncology testing, with an expectation of continued product expansion and adoption. The firm’s revised price target and reiterated Buy rating reflect confidence in the company’s commercial traction and the potential impact of regulatory and coverage decisions on future revenue streams.
Key points
- BTIG reiterates Buy on Guardant Health and raises its price target to $195, citing a strong Q2 beat and raised guidance.
- Q2 revenue was $335 million, up 44% year-over-year, supported by a 63% increase in core oncology testing volume.
- Guardant’s leadership in liquid biopsy is reinforced by a substantial clinical trial program, including the approximately 20,000-patient ECLIPSE study; sectors impacted include healthcare diagnostics, biotechnology and oncology-focused markets.
Risks and uncertainties
- Adoption of Guardant’s oncology, screening and MRD applications remains at early stages, creating uncertainty around the pace of commercial uptake across healthcare settings.
- Potential CMS coverage decisions for Reveal MRD are not guaranteed and could materially affect reimbursement dynamics; the outcome of such regulatory or payer decisions is a key uncertainty impacting revenue for diagnostic testing providers.
- Product launch timelines and regulatory pathways, including the planned launch of Reveal Ultra MRD in the second half of 2026 and the pursuit of ADLT status for G360 Smart Liquid with an expected first-half 2027 launch, are subject to execution and approval risks that could influence market adoption and pricing.